Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors.
Claude NégrierJohannes OldenburgGili KenetShannon L MeeksJean-Claude BordetJens MüllerSandra Le QuellecPeter L TurecekNikola TripkovicDargaud YesimPublished in: Research and practice in thrombosis and haemostasis (2022)
Recombinant porcine factor VIII demonstrated a dose-dependent correction of thrombin generation and clot formation in vitro, dependent on the anti-porcine FVIII inhibitor titer. Procoagulant responses to rpFVIII occurred in plasma containing FVIII inhibitors.
Keyphrases